bluuebunny/crossref_metadata_2025_split huggingface dataset:
WT1 Synonymous Single Nucleotide Polymorphism rs16754 Correlates With Higher mRNA Expression and Predicts Significantly Improved Outcome in Favorable-Risk Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group
Authors: Ho Phoenix A. , Kuhn Julia , Gerbing Robert B. , Pollard Jessica A. , Zeng Rong , Miller Kristen L. , Heerema Nyla A. , Raimondi Susana C. , Hirsch Betsy A. , Franklin Janet L. , Lange Beverly , Gamis Alan S. , Alonzo Todd A. , Meshinchi Soheil 
Published: December 2010

Purpose To analyze the prevalence and clinical implications of Wilms' tumor 1 (WT1) single nucleotide polymorphism (SNP) rs16754 in the context of other prognostic markers in pediatric acute myeloid leukemia (AML). Patients and Methods Available diagnostic marrow specimens (n = 790) from 1,328 patients enrolled in three consecutive Children's Cancer Group/Children's Oncology Group trials were analyzed for the presence of SNP rs16754. SNP status was correlated with disease characteristics, WT1 expression level, and clinical outcome. Results SNP rs16754 was present in 229 (29%) of 790 patients. The SNP was significantly more common in Asian and Hispanic patients and less common in white patients (P < .001). SNP rs16754 was also less common in patients with inv(16) (P = .043) and more common in patients with −5/del(5q) (P = .047). WT1 expression levels were significantly higher in patients with rs16754 or with WT1 mutations compared with WT1 wild-type patients (P = .021). Five-year overall survival (OS) for patients with and without the SNP was 60% and 50%, respectively (P = .031). Prognostic assessment by risk group demonstrated that in patients with low-risk disease, OS for those with and without SNP rs16754 was 90% versus 64% (P < .001) with a corresponding disease-free survival of 72% versus 53% (P = .041). Conclusion The presence of SNP rs16754 was an independent predictor of improved OS; outcome differences were most pronounced in the low-risk subgroup. The high prevalence of WT1 SNP rs16754, and its correlation with improved outcome, identifies WT1 SNP rs16754 as a potentially important molecular marker of prognosis in pediatric AML.
Pediatric End-of-Life Care for Taiwanese Children Who Died As a Result of Cancer From 2001 Through 2006
Authors: Tzuh Tang Siew , Hung Yen-Ni , Liu Tsang-Wu , Lin Dong-Tsamn , Chen Yueh-Chih , Wu Shiao-Chi , Hsia Hsu Tsui 
Published: December 2010

Purpose Patterns of aggressive end-of-life (EOL) care have not been extensively explored in a pediatric cancer population, especially outside Western countries. The purpose of this population-based study was to examine trends in aggressive pediatric EOL cancer care in Taiwan. Methods Retrospective cohort study that used administrative data among 1,208 pediatric cancer decedents from 2001 through 2006. Results Taiwanese pediatric cancer patients who died in 2001 through 2006 received aggressive EOL care. The majority of these patients in their last month of life continued to receive chemotherapy (52.5%), used intensive care (57.0%), underwent intubation (40.9%), underwent mechanical ventilation (48.2%), or spent greater than 14 days (69.5%) in hospital, and they died in an acute care hospital (78.8%). Of these pediatric cancer patients, one in four received cardiopulmonary resuscitation in the month before they died, and only 7.2% received hospice care. Among those who received hospice care, 21.8% started such care within the last 3 days of life. This pattern of aggressive EOL care did not change over the study period except for significantly decreased intubation in the last month of life. Conclusion Continued chemotherapy and heavy use of life-sustaining treatments in the last month of life coupled with lack of hospice care to support Taiwanese pediatric cancer patients dying at home may lead to multiple unplanned health care encounters, prolonged hospitalization at EOL, and eventual death in an acute care hospital for the majority of these patients. Future research should design interventions that enable Taiwanese pediatric cancer patients to receive EOL care that best meets the individual or the parental needs and preferences.
Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Chemotherapy With or Without Bevacizumab in Patients With Resected Hepatic Metastases From Colorectal Cancer
Authors: Kemeny Nancy E. , Jarnagin William R. , Capanu Marinela , Fong Yuman , Gewirtz Alexandra N. , DeMatteo Ronald P. , D'Angelica Michael I. 
Published: December 2010

Purpose Add systemic bevacizumab (Bev) to adjuvant hepatic arterial infusion (HAI) plus systemic therapy after liver resection to increase recurrence-free survival (RFS). Patients and Methods Patients were randomly assigned to HAI plus systemic therapy with or without Bev. If 1-year RFS of ≥ 80% was obtained in Bev arm, then the regimen would be studied further. HAI with fluorodeoxyuridine plus dexamethasone was given on days 1 to 14 of a 5-week cycle. Systemic therapy and Bev 5 mg/kg was delivered on days 15 and 29: oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2,000 mg/m2 infusion for 2 days (if patients received prior oxaliplatin, then irinotecan 150 mg/m2 was used). RFS and survival were estimated by using the Kaplan-Meier method and compared by using the log-rank test. Results The two arms had similar characteristics: synchronous disease (66% v 63%), more than one metastasis (84% v 74%), and clinical risk score ≥ 3 (50% v 46%) for no Bev versus Bev arms, respectively. With a median follow-up of 30 months, 4-year survival was 85% and 81% (P = .5), and 4-year RFS was 46% versus 37%; 1-year RFS was 83% and 71% (P = .4) for no Bev versus Bev arms. Bilirubin > 3 mg/dL was seen in zero of 38 versus five of 35 patients (P = .02) and biliary stents were placed in zero versus four patients (P = .05) in no Bev versus Bev arms. Conclusion The addition of Bev to adjuvant HAI plus systemic therapy after liver resection did not seem to increase RFS or survival but appeared to increase biliary toxicity. Four-year survival was 85% and 81% for no Bev and Bev arms, respectively.
Use of Risperidone as Augmentation Treatment for Major Depressive Disorder
Authors: Owenby Ryan K , Brown Lindsey T , Brown Jamie N 
Published: December 2010

Objective To review the efficacy and safety of risperidone for augmentation treatment In patients with major depressive disorder who fail to achieve adequate response to antidepressant monotherapy. Data Sources: A search of MEDLINE (1966-August 2010) and EMBASE (1980-August 2010) was conducted, using the terms risperidone and major depressive disorder. In addition, a manual search of the references cited in each publication identified from the database search was conducted to identify relevant articles. Study Selection And Data Extraction: All English-language, peer-reviewed publications identified from the data sources were evaluated. Four clinical trials and 1 subanalysis of a clinical trial were included for analysis. Data Synthesis: Risperidone is an atypical antipsychotic that displays antidepressant properties due to its activity at various serotonergic and dopaminergic receptors. Studies have demonstrated that risperidone augmentation may be effective and safe when used at low doses. Although several of the studies identified had limited sample sizes, all studies demonstrated improvement on various standardized depressive symptom assessment scales. Study durations ranged from 4 to 24 weeks, with doses ranging from 0.25 to 2 mg/day. The most common adverse effects associated with risperidone therapy were headache, dry mouth, and increased appetite. Conclusions: Clinical evidence suggests that the use of risperidone as adjunctive therapy for treatment-resistant depression may improve rates of response and remission, but long-term effectiveness and safety cannot be determined at this time. Therefore, an adequate trial of first-line agents from different classes and/or a combination of agents from different classes would be recommended prior to initiation of risperidone. If the decision is made to start risperidone, health-care providers should ensure that patients are educated regarding the potential benefits and adverse effects before initiating risperidone.
The Role of Lamotrigine in the Treatment of Short-Lasting Unilateral Neuralgiform Headache Attacks with Conjunctival Injection and Tearing Syndrome
Authors: Rosselli Jennifer L , Karpinski Julie P 
Published: December 2010

Objective To evaluate the efficacy of lamotrigine for treatment of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) syndrome. Data Sources: Literature was accessed through MEDLINE (1950-June 2010) using the terms lamotrigine, triazines, SUNCT, and trigeminal autonomic cephalgia. Study Selection And Data Extraction: All articles in English and studies conducted in humans were identified and evaluated. Data Synthesis: SUNCT syndrome can be an extremely challenging headache type to manage and has been considered refractory to pharmacotherapy. Many anticonvulsants have been evaluated as promising SUNCT treatments, with lamotrigine specifically reported as an effective first-line treatment option. There is a lack of randomized placebo-controlled clinical trials evaluating lamotrigine in SUNCT syndrome therapy; however, 2 observational studies, 3 case series, and 5 case reports were reviewed. Lamotrigine appears to decrease the frequency and severity of SUNCT attacks, leading to complete resolution in some patients. A decrease in symptoms was achieved with doses ranging from 25 to 600 mg/day. In some cases, there was initial response to low doses, but dosage titrations were often necessary when symptoms returned several days after being managed at the same dose. Lamotrigine should be initiated at 25 mg/day and gradually titrated, guided by response and adverse effects. The risk of Stevens-Johnson syndrome, a dose-related adverse effect, can be minimized with gradual titration. Conclusions: According to case reports and observational studies, lamotrigine therapy has resulted in decreased frequency or resolution of SUNCT syndrome attacks. Randomized, controlled trials are necessary to confirm the efficacy of lamotrigine for this indication.
Autoimmune Hemolytic Anemia Following MF59-Adjuvanted Influenza Vaccine Administration: A Report of Two Cases
Authors: Montagnani Sabrina , Tuccori Marco , Lombardo Giuseppe , Testi Arianna , Mantarro Stefania , Ruggiero Elisa , Blandizzi Corrado 
Published: December 2010

Objective To describe 2 cases of autoimmune hemolytic anemia (AIHA) following the administration of MF59-adjuvanted influenza vaccine. Case Summary: An 83-year-old white woman developed persistent hyperpyrexia, polyarthralgia, and lower limb hypostenia about 2 days after receiving influenza vaccine. Clinical signs and laboratory evaluations suggested AIHA. The patient was treated with high-dose corticosteroids and immunoglobulins, and her clinical condition improved. A 74-year-old white woman developed severe abdominal pain and asthenia 3 days after the administration of influenza vaccine. Clinical signs and laboratory evaluations disclosed AIHA. She was treated with corticosteroids, rehydration, and blood transfusion; however, she died about 48 hours after hospitalization. Discussion: AIHA has been rarely described following influenza vaccine administration. In the cases described here, the causal relationship between influenza vaccination and the occurrence of AIHA, assessed by means of World Health Organization criteria, was scored as probable. It has been proposed that the mechanism whereby vaccines induce autoimmune responses can be molecular mimicry, although a possible role of other vaccine constituents, with particular regard for adjuvants, such as MF59, can not be excluded. Squalene, a constituent of MF59, has been suggested as a causative agent of autoimmune reactions. However, it is not clear how and under what conditions squalene can cause immune responses. Conclusions: Influenza vaccination may rarely trigger severe AIHA, shortly after vaccine administration. A mechanism of molecular mimicry is probably involved in the development of these reactions, although the possible role of adjuvants can not be excluded. Patients should be instructed to report signs and symptoms of autoimmune disorders occurring in the first weeks after administration of influenza vaccine.
Magnitude and Direction of Mechanical Stress at the Osseointegrated Interface of the Microthread Implant
Authors: Hudieb Malik I. , Wakabayashi Noriyuki , Kasugai Shohei 
Published: December 2010

Background: The mechanism by which the microthread implant preserves peri‐implant crestal bone is not known. The objective of this research is to assess the effect of microthreads on the magnitude and direction of the stress at the bone–implant interface using finite element analysis modeling.Methods: Three‐dimensional finite element models representing the microthreaded implant (microthread model) and smooth surface implant (smooth model) installed in the mandibular premolar region were created based on microscopic and computed tomography images. The mesh size was determined based on convergence tests. Average maximum bite force of adults was used with four loading angles on the occlusal surface of the prosthesis.Results: Regardless of the loading angle, principal stresses at the bone–implant interface of the microthread model were always perpendicular to the lower flank of each microthread. In the smooth model, stresses were affected by the loading angle and directed obliquely to the smooth interface, resulting in higher shear stress. The interfacial stresses decreased gradually in the apical direction in both models but with wavy pattern in the microthread model and smooth curve for the smooth model. Although peak principal stress values were higher around the microthread implant, peri‐implant bone volume exhibiting a high strain level >4,000 μ was smaller around the microthread implant compared to the smooth implant.Conclusion: Stress‐transferring mechanism at the bone–implant interface characterized by the direction and profile of interfacial stresses, which leads to more compressive and less shear stress, may clarify the biomechanical aspect of microthread dental implants.
The Effects of Er:YAG Laser Treatment on Titanium Surface Profile and Osteoblastic Cell Activity: An In Vitro Study
Authors: Galli Carlo , Macaluso Guido M. , Elezi Erida , Ravanetti Francesca , Cacchioli Antonio , Gualini Giacomo , Passeri Giovanni 
Published: December 2010

Background: Laser light has been proposed as a tool to decontaminate the surface of endosseous implants. The effects of this maneuver on the interactions between cells and surface, however, are poorly known. The goal of the present study is to investigate osteoblast growth and differentiation on three commercially available surfaces untreated or after irradiation by erbium‐doped:yttrium, aluminum, and garnet (Er:YAG) laser at two levels: 150 and 200 mJ/pulse at 10 Hz.Methods: Human osteoblastic Saos‐2 cells were plated on machined, sandblasted and acid‐etched titanium, or titanium plasma‐sprayed disks. The effects of lasing were observed with a scanning electronic microscope, and cell viability was measured by 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide assay. Moreover, we measured the production of the osteoblast‐specific protein osteocalcin and of osteoprotegerin in the supernatants by immunoenzymatic assays.Results: Although no visible changes were observed on machined or titanium plasma‐sprayed disk samples at the tested levels, titanium peaks on sandblasted and acid‐etched titanium disks appeared fused as a consequence of laser irradiation. Interestingly, cell proliferation was slower on irradiated titanium at both intensities on all the surfaces. Cell differentiation, as assessed by osteocalcin production, was generally unaffected by laser treatment, whereas the production of osteoprotegerin was decreased on all the surfaces irradiated at the intensity of 200 mJ/10Hz.Conclusions: These results indicate that Er:YAG laser at energy levels used in this study can alter the surface profile of titanium implants and these changes may negatively affect the viability and the activity of osteoblastic cells. Therefore, Er:YAG lasers should be used with caution on titanium surfaces.
Chronic Periodontitis and C‐Reactive Protein Levels
Authors: Gomes‐Filho Isaac Suzart , Freitas Coelho Julita Maria , da Cruz Simone Seixas , Passos Johelle Santana , Teixeira de Freitas Camila Oliveira , Aragão Farias Naiara Silva , Amorim da Silva Ruany , Silva Pereira Milena Novais , Lima Thiago Lopes , Barreto Maurício Lima 
Published: December 2010

Background: This study aims to analyze the relationship between chronic periodontitis and C‐reactive protein (CRP) by considering associated variables in individuals with or without cardiovascular disease.Methods: A sample of 359 individuals of both sexes (aged ≥40 years) was assessed. Among these individuals, 144 subjects were admitted to the hospital because of a first occurrence of acute myocardial infarction; 80 subjects were in the hospital for reasons other than acute myocardial infarction; and 135 subjects were living in the community. A questionnaire was applied to obtain demographic and lifestyle characteristics. Complete clinical periodontal examinations and anthropometric assessments were performed. CRP levels, plasma glucose levels, lipid profiles, and blood tests were performed to investigate any conditions that might have suggested infection and/or inflammation. CRP evaluations were performed using nephelometry. Individuals were considered to have periodontal disease if they simultaneously presented at least four teeth with one or more sites with probing depth ≥4 mm, clinical attachment loss ≥3 mm, and bleeding on probing. Procedures for descriptive analyses and logistic regression were used.Results: In the chronic periodontitis group, mean CRP levels were higher than those in the group without chronic periodontitis (2.6 ± 2.6 mg/L versus 1.78 ± 2.7 mg/L, respectively). The final model showed that individuals with chronic periodontitis were more likely to have high CRP levels (adjusted odds ratio: 2.26; 95% confidence interval: 1.30 to 3.93) considering the effects of age, schooling level, sex, smoking, high‐density lipoprotein cholesterol, and diabetes.Conclusion: In this study, chronic periodontitis is associated with elevated plasma CRP levels, even after controlling for several potential confounders.
Bone Morphogenetic Protein‐7 Modifies the Effects of Insulin‐Like Growth Factors and Intermittent Parathyroid Hormone (1‐34) on Human Periodontal Ligament Cell Physiology In Vitro
Authors: Lossdörfer Stefan , Abuduwali Nuersailike , Jäger Andreas 
Published: December 2010

Background: Components of the insulin‐like growth factor (IGF) system and intermittent parathyroid hormone (PTH) were demonstrated to exert anabolic effects on the periodontal ligament (PDL) and, thereby, contribute to the regeneration of structures that were lost because of inflammatory periodontal disease.Methods: In the present study, a PDL cell culture is created to examine whether a combination of IGFs and intermittent PTH would enhance the cellular response elicited by each factor alone and addressed the question of whether a pretreatment of the cells with bone morphogenetic protein (BMP)‐7 alters the PDL cell phenotype and behavior on IGF‐PTH stimulation.Results: IGF‐I and IGF‐II enhanced proliferation and differentiation in preconfluent and confluent cultures. A BMP‐7 pretreatment inhibited those effects in preconfluent cells but not in confluent cultures. Intermittent PTH (1‐34) inhibited the proliferation but stimulated the differentiation of preconfluent cells, whereas the opposite effect was observed in confluent cultures. BMP‐7 prestimulation made preconfluent cells respond like confluent cultures on intermittent PTH (1‐34) challenge. A combined administration of PTH (1‐34) and IGF‐I or IGF‐II mostly mirrored the effects seen for one of the individual agents alone, but synergistic effects were not observed.Conclusions: The present data indicate that both PTH (1‐34) and IGF‐I or IGF‐II exert a maturation stage‐dependent effect on PDL cell proliferation and differentiation. Combining PTH (1‐34) and IGF does not seem to potentiate the effects seen for the agents alone. Furthermore, our data suggest that BMP‐7 induces preconfluent cells to acquire a more differentiated phenotype and to respond to intermittent PTH (1‐34) accordingly. Confluent cultures seem to be less susceptible to BMP‐7.
Is Platelet Concentrate Advantageous for the Surgical Treatment of Periodontal Diseases? A Systematic Review and Meta‐Analysis
Authors: Del Fabbro Massimo , Bortolin Monica , Taschieri Silvio , Weinstein Roberto 
Published: December 2010

Background: The aim of the present review is to systematically evaluate the effects of autogenous platelet concentrates on clinical outcomes of the surgical treatment of periodontal diseases.Methods: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched using a combination of specific search terms. Furthermore, a hand search of relevant journals and bibliographies of reviews was performed. Only randomized clinical trials were included. For periodontal intrabony defects, the primary outcome variable was the clinical attachment level. For gingival recession, outcome variables were root coverage and keratinized tissue increase. Data were adjusted for baseline values. The methodologic quality of the included studies was assessed. The results of studies in which the only difference between test and control groups was the adjunct of platelet concentrates were aggregated using a meta‐analysis. For intrabony defects, the influences of guided tissue regeneration (GTR) and study type (split‐mouth versus parallel studies) were also evaluated.Results: The initial search yielded 424 studies. Of the 29 eligible studies, 24 studies were included. There were16 studies on the treatment of periodontal intrabony defects, all of which used platelet‐rich plasma (PRP); six studies on gingival recession treatment; and two studies on the treatment of furcation defects. A significant positive effect of the adjunct of PRP was found for intrabony defects. Such an effect was magnified in studies in which GTR was not used, whereas in studies using GTR, the use of PRP had no adjunctive effect. No effect of the study type was found. No significant effect of platelet concentrates was found for gingival recession treatment in which only studies with a follow‐up ≤6 months displayed positive results. No significant benefit of PRP could be demonstrated for furcation treatment.Conclusions: PRP may exert a positive adjunctive effect when used in combination with graft materials, but not with GTR, for the treatment of intrabony defects. No significant benefit of platelet concentrates was found for the treatment of gingival recession.